NanoCarrier Co., Ltd.

The R&D of new drugs with proprietary polymer

Focusing on nucleic acid drugs such as mRNA early, we are working toward the clinical stage of the ASO drug for glioblastoma and the mRNA regenerative medicine for osteoarthritis in addition to on-going investigator-initiated Phase I study of siRNA drug for refractory TNBC.

電話アイコン +81-44-589-8832
メールアイコン https://www.nanocarrier.co.jp/en/contact/

iCONM

Drug Discovery/Drug Discovery Support

  • Pharmaceuticals
  • Regenerative Medicine
  • Healthcare